Close Menu

NEW YORK (GenomeWeb) – Children with a certain brain tumor subtype may benefit from the addition of bevacizumab to their treatment regimens, according to a new study.

A team led by researchers from the Institute of Cancer Research, London used data from the HERBY phase 2 trial — which analyzed how well children with non-brainstem high-grade glioma fared when bevacizumab (sold as Avastin in the US) was added to their treatment regimen — found that patients whose tumors had mutations within genes in the MAPK network appeared to benefit from the added treatment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
17

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.